BNET Industries
Market Cap:$1.3M
Last Fiscal Year Sales:$106.0K
- Public
- US
Dow Jones Description
Alliance Pharmaceutical Corp. (the "Company" or "Alliance") is a pharmaceutical research and development company that focuses on developing scientific discoveries into medical products for human health applications. Imagent(R) (formerly named Imavist(TM)), has been approved for sale in the U.S. as an intravenous contrast agent for enhancement of ultrasound images to assess cardiac structure and motion. In the past year, the Company entered into an Asset Purchase Agreement with Photogen Technologies, Inc. ("Photogen") whereby Photogen acquired all of the assets related to designing, developing, manufacturing, marketing, selling, licensing, supporting and maintaining Imagent (collectively, the "Imagent Business") and assumed certain of the Company's liabilities. Another of the Company's products, Oxygent(TM), is in clinical development as an intravascular oxygen carrier to reduce the need for donor blood in surgical and other patients at risk of acute tissue hypoxia (oxygen deficiency). Through its 100%-owned subsidiary, Astral, Inc. ("Astral"), the Company has developed intellectual property and know-how for potential products to treat immune disorders, including autoimmune disease, cancer, and infectious diseases.
Chairman and Chief Executive Officer
Duane RothNumber of Employees 1
Contact Information
4660 La Jolla Village Dr Ste 825
San Diego, California 92122
(858) 410-5275 (Corp Comm)
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
News & Analysis
Filter by
alliance pharmaceutical corp. - All News and Analysis
Corporate Profile for Alliance Pharmaceutical Corp., dated April 24, 1998
--BUSINESS WIRE--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0- Published Date: April 24, 1998 Company...
Alliance Pharmaceutical Corp. announces additional board member
SAN DIEGO--BUSINESS WIRE--Aug. 19, 1996--Alliance Pharmaceutical Corp. Monday announced that Pedro Cuatrecasas, M.D., was elected to its board of directors at a directors meeting on Aug. 13, 1996.Cuatrecasas is presently vice president of Warner-Lambert Co. and president, pharmaceutical research, of Parke-Davis in Ann Arbor, Mich.Cuatrecasas has more than 20 years'...
Alliance Pharmaceutical Corp. announces public offering
SAN DIEGO--BUSINESS WIRE--April 2, 1996--Alliance Pharmaceutical Corp. (NASDAQ:ALLP) Tuesday announced that its public offering of 2,500,000 shares of common stock has been declared effective.The shares have been offered at a price of $16.50 per share by Lehman Brothers, Cowen & Co. and Oppenheimer & Co. Inc., the managing underwriters for...
Alliance Pharmaceutical Corp. announces public offering
SAN DIEGO--BUSINESS WIRE--April 21, 1995--Alliance Pharmaceutical Corp. (NASDAQ:ALLP) Friday announced that its public offering of 3,175,000 shares of common stock has been declared effective.The shares have been offered by the company at a price of $5 per share. Oppenheimer & Co. Inc. Oppenheimer and Cowen & Co. Cowen acted...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| B. Jack Defranco | President and Chief Operating, Officer |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Duane Roth | Chairman and Chief Executive Officer |
| Stephen M. McGrath | Audit Committee Chairman |
| Caroll O. Johnson | Board of Directors |
| Carroll O Johnson | Board of Directors |
| Jean Riess | Board of Directors |
| Pedro Cuatrecasas | Board of Directors |
| Theodore D. Roth | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| UCSD-CONNECT | Chief Executive Officer | Current |
| Alliance Pharmaceutical Corp | Chairman and Chief Executive Officer | Current |
| UCSD-CONNECT | Director | Current |
| University of California | Board Member | Current |
| San Diego Regional Chamber of Commerce | Board Member | Current |
| Alliance Pharmaceutical Corp | Founder | Former |
| Johnson & Johnson | Senior Management Positions | Former |
| American Home Products Corporation | Senior Management Positions | Former |
| The San Diego Foundation | Board of Directors | Former |
| Biotechnology Industry Organization | Director | Former |
| Biocom, Inc. | Board of Directors | Former |
| California Healthcare Institute, Inc. | Director | Former |
| Organization | Position | Status |
|---|---|---|
| Alliance Pharmaceutical Corp | President and Chief Operating, Officer | Current |
| Imcor Pharmaceutical Co | Chief Operating Officer | Former |
| Imcor Pharmaceutical Co | Senior Vice President | Former |
| Fairleigh Dickinson University | Masters In Finance | Former |
| Stephen F. Austin State University | BS In Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Alliance Pharmaceutical Corp | Audit Committee Chairman | Current |
| Sterling Drug | Controller | Former |
| Sterling Drug | Assistant Treasurer | Former |
| Warner-Lambert | Former | |
| Warner-Lambert Company | Former | |
| Sterling Drug | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Alliance Pharmaceutical Corp | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Alliance Pharmaceutical Corp | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Alliance Pharmaceutical Corp | Board of Directors | Current |
PEDRO CUATRECASAS, M.D. Dr. Cuatrecasas has served as a director of the Company since August 1996. He has over 35 years of experience in the pharmaceutical industry. Dr. Cuatrecasas retired from the positions of Vice President of Warner-Lambert Company and President, Parke-Davis Pharmaceutical Research on December 31, 1996, positions he had held since 1989. During the previous four years, he had been Senior Vice President of Research and Development and Director of Glaxo, Inc. For the prior ten years, he was Vice President of Research, Development and Medical and Director of Burroughs Wellcome Company. Dr. Cuatrecasas is a member of the National Academy of Sciences and the Institute of Medicine. He is currently an independent consultant in pharmaceutical research and an Adjunct Professor in Medicine and Pharmacology at the University of California in San Diego. He received his M.D. from Washington University School of Medicine. Dr. Cuatrecasas qualifies as an "independent" director within the meaning of Rule 4200(a)(15) of the NASD Listing Standards.
| Organization | Position | Status |
|---|---|---|
| University of California | Adjunct Professor | Current |
| Mehta Partners - Global Healthcare Investments | Current | |
| National Academy of Sciences | Board of Directors | Current |
| Alliance Pharmaceutical Corp | Board of Directors | Current |
| Aethlon Medical, Inc. | Board of Directors | Current |
| National Academy of Sciences | Member | Current |
| Burroughs Wellcome Co. - USA | Vice President of Research and Development | Former |
| Burroughs Wellcome Co. - USA | Director | Former |
| Washington University School of Medicine | M.D. | Former |
| Washington University | M.D. (Magna Cum Laude) | Former |
Ted Roth joined Roth Capital Partners in 2003, following 15 years with Alliance Pharmaceutical Corp., a publicly-owned specialty pharmaceutical development company, most recently serving as President and Chief Operating Officer. On behalf of the company, he negotiated and executed several multi-million dollar collaborations, acquisitions, and divestitures, as well as public and private financing transactions. Prior to Alliance, he spent 10 years with a privately-held manufacturing company in various financial and management positions. He is on the Board of Directors of Alliance Pharmaceutical and BioMed Realty Trust, Inc (NYSE:BMR). Mr. Roth is also a member of the Boards of Directors of the San Diego Regional Chamber of Commerce (2002 Chairman), San Diego Children's Hospital & Health Center, the San Diego Padres Baseball Team, San Diego International Sports Council (2005 Chairman), the Pacific Life Holiday Bowl, BIOCOM/San Diego, and High Tech High School. He is past Chair of the California Democratic Leadership Council. He is a graduate of Iowa Wesleyan College, and has a J.D. from Washburn University and an LL.M. from the University of Missouri in Kansas City.
| Organization | Position | Status |
|---|---|---|
| Roth Capital Partners LLC | President and Chief Operating Officer | Current |
| San Diego Regional Chamber of Commerce | Special Team | Current |
| Bmr Inc | Board of Directors | Current |
| UCSD-CONNECT | Director | Current |
| San Diego Regional Chamber of Commerce | Board Director | Current |
| Edvoice.Org | Board of Directors | Current |
| Alliance Pharmaceutical Corp | Board of Directors | Current |
| BioMed Realty Trust, Inc. | Director | Current |
| Padres L.P. | Board of Directors | Current |
| Orange 21 Inc. | Board of Directors | Current |
| Padres L.P. | Member | Current |
| San Diego International Sports Council | Member | Current |
| Alliance Pharmaceutical Corp | President | Former |
| Roth Capital Partners LLC | Managing Director | Former |
| San Diego International Sports Council | Board Member | Former |
| Pacific Life Holiday Bowl | Board Member | Former |
| Washburn University | Juris Doctor Degree | Former |
| University of Missouri | Master of Laws In Corporate and Commercial Law | Former |
| University of Missouri-Kansas City | LL.M | Former |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes

